Navigation Links
Clinical Financial Services (CFS) Launches New Service to Streamline Clinical Trial Activation
Date:5/17/2011

PHILADELPHIA, May 17, 2011 /PRNewswire/ -- As part of its ongoing mission to provide comprehensive business and financial management solutions in support of clinical trials, Clinical Financial Services (CFS) is pleased to announce the launch of its newest offering, Site Activation Services. This revolutionary new service, which includes regulatory document collection and management as well as global investigator budget and contract management, will streamline and automate the trial activation process and minimize financial risk for clinical trial sponsors, CROs, and investigative sites.

Headed by an experienced team dedicated to managing the complex tasks required to activate investigator sites, CFS can accelerate clinical trial cycle times by maximizing the number of sites that are activated and "enrollment ready" when the enrollment phase of the trial begins.

  • By pre-populating regulatory and financial disclosure documents with data from an enterprise-wide proprietary database, CFS ensures the accuracy of site and investigator information, prevents redundancy and speeds the time it takes to complete this paperwork.
  • Through extensive audit capabilities, CFS ensures that financial disclosure information is compliant with 21CFR Part 54 and internal SOPs, consistent with Form FDA 1572 and aligned with aggregate spend payment data.
  • With a robust global legal network operating in more than 60 countries, CFS supports complex contract negotiations around the world.
  • By offering a technologically advanced project dashboard that is available 24/7, CFS offers unprecedented visibility into the status of every trial start-up document.

"With complicated regulatory documentation, tight timelines, and the newly passed Sunshine Act, proper business and financial management of clinical trials is more important than ever," says Greg Seminack, CFS President and Managing Partner. "Partnering with CFS not only allows sponsor organizations to manage these requirements efficiently and cost-effectively, but it significantly improves investigator relationships and ultimately helps get drugs to market faster."

In addition to Site Activation Services, CFS rounds out its product offering with Global Contract Management and Global Payment Management Services.

About CFS

Clinical Financial Services (CFS) is the only company that offers comprehensive business and financial management services for the clinical trials industry. CFS manages clinical trial budgets and agreements, contract negotiation and administration, regulatory documentation, and finance and accounting.  Founded in January 2001, CFS is headquartered in Audubon, PA.  For more information, visit www.clinicalfinancialservices.com

Contact:
Micheal Cavanaugh
Clinical Financial Services, LLC
610-994-2771
mcavanaugh@clinicalfinancialservices.com


'/>"/>
SOURCE Clinical Financial Services
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ACT Announces Oregon Health & Science University as Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration
2. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
3. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
4. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
5. ALTITUDE Clinical Data Show ICD Therapy Saves Lives Without Mortality Increase from Device Shock
6. Adeonas Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant
7. Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World
8. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
9. Omnicare Clinical Research Acquired by Nautic Partners, LLC
10. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
11. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
(Date:3/23/2017)... , March 23, 2017 NetworkNewsWire ... ... death, putting significant strain on health care systems, in terms ... diagnoses rises, so too does the development of innovative and ... side effects. Among the many types of cancer treatments, a ...
(Date:3/23/2017)... La. (PRWEB) , ... March 23, 2017 , ... ... industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as ... customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has ...
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):